HANDOK Inc. of Seoul at MEDICA 2020 in Düsseldorf -- COMPAMED Trade Fair
Manage stand orders
Select Option

HANDOK Inc.

132, Teheran-Ro, Gangnam-gu, 06235 Seoul
Korea, Republic
Telephone +82 2 5275273
Fax +82 2 5275004
mdls@handok.com

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

Media files

Contact

HeeYoung Na

Phone
+82-2-527-5151

Email
chexel@handok.com

Our range of products

Product categories

  • 03  Diagnostic tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.02  Diagnostic rapid tests

Our products

Product category: Diagnostic rapid tests

[COVID-19 IgM/IgG Test] CHEXEL™, Check-up Excellence

CHEXEL™  COVID-19 IgM/IgG Test Kit (CAT# GQLAGH)
- CE marking will be completed in December 2020

KEY FEATURES & BENEFITS
- Accurate & compact/Easy-to-use
- Rapid immunoassay
- Small sample volume analysis
- High sensitivity & high reproducibility

More Less

Product category: Diagnostic rapid tests

[COVID-19 Antigen Test] CHEXEL™, Check-up Excellence

CHEXEL™  COVID-19 Antigen Test Kit
- Launching is expected in December 2020
- CE marking is expected in Q1 2021

KEY FEATURES & BENEFITS
- Accurate & compact/Easy-to-use
- Rapid immunoassay
- Small sample volume analysis
- High sensitivity & high reproducibility

More Less

Product category: Diagnostic rapid tests

[Cardiac TnI Test System] CHEXEL™, Check-up Excellence

CHEXEL™  Cardiac TnI Test System
- Launching is expected in Q2 2021
- CE marking is expected in Q4 2021

KEY FEATURES & BENEFITS
- Rapid immunoassay
- Small sample volume analysis
- High sensitivity & high reproducibility (TnI LoQ=0.1 ul/mL)

More Less

About us

Company details

The Health Innovator, Handok

Handok (Chairman & CEO Young-Jin Kim) is committed to innovation and its business has grown both through strategic partnerships with other companies as well as through innovative research. Handok was founded in 1954 and has been listed on the Korea Stock Exchange since 1976. The company has never recorded a deficit year since establishment.

Handok grew as a joint venture with Hoechst/Aventis/Sanofi from 1964 to 2012. Handok has also established strategic collaborations in several areas with multiple multinational pharmaceutical companies. Handok ended its joint venture relationship with Sanofi in 2012 and became an independent company again. Handok changed its company name from Handok Pharmaceutical Co., Ltd to Handok Inc. and declared its vision to become “The Health Innovator” and as Korea’s leading global healthcare company. Handok introduces new products to the Korean market through partnerships, internal R&D, and state-of-the-art manufacturing while maintaining a global standards compliance program.

Handok is a total healthcare company. Handok’s businesses mainly focus on prescription drugs along with consumer health care products, medical devices and in vitro diagnostics, food supplements and medical nutrition.

Handok is one of the leading pharmaceutical companies which highly value ethical business practices. It has fully implemented comprehensive codes of conduct. This commitment has been recognized with the Special Ethical Management Award conferred by the Health Industry CEO Summit in 2008 and the Excellence prize for Transparent Management by Korea’s five major economic organizations including KEF, FKI in 2010.

More Less